Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have been given a consensus rating of “Moderate Buy” by the fifteen research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, twelve have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $34.25.

A number of brokerages have recently commented on DNLI. HC Wainwright lifted their target price on shares of Denali Therapeutics from $32.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Leerink Partners cut their target price on shares of Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, April 22nd. Robert W. Baird lifted their price objective on shares of Denali Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Morgan Stanley set a $35.00 price objective on shares of Denali Therapeutics in a research report on Friday. Finally, Wolfe Research started coverage on shares of Denali Therapeutics in a research report on Monday, February 23rd. They issued a “peer perform” rating on the stock.

Hedge Funds Weigh In On Denali Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of DNLI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Denali Therapeutics by 4.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company’s stock valued at $1,210,000 after buying an additional 3,432 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Denali Therapeutics by 58.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock valued at $22,732,000 after buying an additional 614,555 shares during the last quarter. Empowered Funds LLC grew its position in Denali Therapeutics by 11.0% in the 1st quarter. Empowered Funds LLC now owns 20,639 shares of the company’s stock valued at $281,000 after buying an additional 2,052 shares during the last quarter. Woodline Partners LP grew its position in Denali Therapeutics by 13.5% in the 1st quarter. Woodline Partners LP now owns 113,517 shares of the company’s stock valued at $1,543,000 after buying an additional 13,517 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Denali Therapeutics by 1.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 191,613 shares of the company’s stock valued at $2,681,000 after buying an additional 3,210 shares during the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock opened at $18.64 on Monday. The firm’s fifty day simple moving average is $19.78 and its 200-day simple moving average is $19.08. The stock has a market capitalization of $2.96 billion, a price-to-earnings ratio of -6.47 and a beta of 0.99. Denali Therapeutics has a 12 month low of $12.58 and a 12 month high of $23.77. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.28 and a quick ratio of 9.28.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, May 7th. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. During the same quarter last year, the firm earned ($0.78) earnings per share. As a group, equities analysts forecast that Denali Therapeutics will post -2.74 earnings per share for the current year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.